Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Shikonin, a natural
naphthoquinone
isolated from a traditional Chinese medicinal herb, which exerts anticancer effects in various cancers. However, the molecular mechanisms underlying the therapeutic effects of shikonin against endometrioid
endometrial cancer
(
EEC
) have not yet been fully elucidated. Herein, we investigated anticancer effects of shikonin on
EEC
cells and explored the underlying molecular mechanism. We observed that shikonin inhibits proliferation in human
EEC
cell lines in a dose-dependent manner. Moreover, shikonin-induced apoptosis was characterized by the up-regulation of the pro-apoptotic proteins cleaved-Caspase-3 and Bax, and the down-regulation of the anti-apoptotic protein Bcl-2. Microarray analyses demonstrated that shikonin induces many miRNAs' dysregulation, and
miR-106b
was one of the miRNAs being most significantly down-regulated.
miR-106b
was identified to exert procancer effect in various cancers, but in
EEC
remains unclear. We first confirmed that
miR-106b
is up-regulated in
EEC
tissues and cells, and knockdown of
miR-106b
suppresses proliferation and promotes apoptosis. Meanwhile, our results validated that the restored expression of
miR-106b
abrogates the antiproliferative and pro-apoptotic effects of shikonin. We also identified that
miR-106b
targets phosphatase and tensin homolog (
PTEN
), a tumor suppressor gene, which in turn modulates AKT/mTOR signaling pathway. Our findings indicated that shikonin inhibits proliferation and promotes apoptosis in human
EEC
cells by modulating the
miR-106b
/PTEN/AKT/mTOR signaling pathway, suggesting shikonin could act a potential therapeutic agent in the
EEC
treatment.
...
PMID:Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating
miR-106b
/PTEN/AKT/mTOR signaling pathway. 2944 46